idraparinux
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
7
Phase 4
0
Earliest trial started May 1, 2003 (NCT00067093)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Coagulation factor XINHIBITOR
F10 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)C(=O)O)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)C(=O)O)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O- Mol. weight
- 1529.35 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1908845 ↗
- ChEMBLCHEMBL5314801 ↗
- ChEMBLCHEMBL5314374 ↗
- ChEMBLCHEMBL1908371 ↗
Also known as
- idraparinux
- idraparinux
- idraparinux sodium
- idraparinux sodium
- idraparinux sodium
- sanorg34006
- sanorg34006
- sanorg34006
- sanorg 34006
- sanorg-34006
- sr34006
- sr34006
- sr34006
- sr 34006
- sr-34006
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00580216 | Phase 3 | Dec 1, 2007 | Sanofi |
| NCT00345618 | Phase 3 | Jun 1, 2006 | Sanofi |
| NCT00311090 | Phase 3 | Apr 1, 2006 | Sanofi |
| NCT00071279 | Phase 3 | Nov 1, 2003 | Sanofi |
| NCT00070655 | Phase 3 | Sep 1, 2003 | Sanofi |
| NCT00062803 | Phase 3 | Jun 1, 2003 | Sanofi |
| NCT00067093 | Phase 3 | May 1, 2003 | Sanofi |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 7 | 7 | 1 | 2003 |
1 organizations
Page 1 / 1